Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Personal CFO Solutions LLC

Personal CFO Solutions LLC increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 55.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,067 shares of the pharmaceutical company’s stock after buying an additional 380 shares during the period. Personal CFO Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $430,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Edgewood Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 7,876.3% during the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company’s stock valued at $719,186,000 after acquiring an additional 1,526,983 shares during the period. WCM Investment Management LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $435,899,000. Jennison Associates LLC lifted its holdings in Vertex Pharmaceuticals by 18.1% in the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after purchasing an additional 851,054 shares during the period. Wellington Management Group LLP lifted its holdings in Vertex Pharmaceuticals by 17.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock valued at $2,231,858,000 after acquiring an additional 704,421 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Vertex Pharmaceuticals by 169.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company’s stock valued at $338,136,000 after acquiring an additional 528,029 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Royal Bank of Canada boosted their price objective on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a report on Thursday, February 20th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. Stifel Nicolaus increased their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research report on Monday, December 16th. Finally, Bank of America reduced their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $506.70.

Vertex Pharmaceuticals Trading Up 0.5 %

Shares of Vertex Pharmaceuticals stock opened at $488.29 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The stock has a 50 day moving average price of $448.27 and a two-hundred day moving average price of $461.15. The stock has a market capitalization of $125.39 billion, a PE ratio of -221.95, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the sale, the executive vice president now directly owns 67,695 shares in the company, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 1,084 shares of company stock worth $505,512. 0.20% of the stock is owned by company insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.